These are cryopreserved, genetically engineered NK cells tailored for the treatment of MM, in which CD38 has been knocked-out using CRISPR-Cas9 technology, and an enhanced CAR-targeting CD38 has been introduced using mRNA electroporation. The gene discussed is CD38; the disease is Miyoshi myopathy.